Design and estimation in clinical trials with subpopulation selection

Population heterogeneity is frequently observed among patients' treatment responses in clinical trials because of various factors such as clinical background, environmental, and genetic factors. Different subpopulations defined by those baseline factors can lead to differences in the benefit or safety profile of a therapeutic intervention. Ignoring heterogeneity between subpopulations can substantially impact on medical practice. One approach to address heterogeneity necessitates designs and analysis of clinical trials with subpopulation selection. Several types of designs have been proposed for different circumstances. In this work, we discuss a class of designs that allow selection of a predefined subgroup. Using the selection based on the maximum test statistics as the worst‐case scenario, we then investigate the precision and accuracy of the maximum likelihood estimator at the end of the study via simulations. We find that the required sample size is chiefly determined by the subgroup prevalence and show in simulations that the maximum likelihood estimator for these designs can be substantially biased.

[1]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[2]  John Whitehead,et al.  Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference 138, 1629-1638. , 2008 .

[3]  Allan R. Sampson,et al.  Extension of a Two-Stage Conditionally Unbiased Estimator of the Selected Population to the Bivariate Normal Case , 2007 .

[4]  Lisa V. Hampson,et al.  Group sequential tests for delayed responses (with discussion) , 2013 .

[5]  J. Whitehead,et al.  A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .

[6]  Mohammad F Huque,et al.  A flexible strategy for testing subgroups and overall population , 2009, Statistics in medicine.

[7]  You-Gan Wang,et al.  Bias Reduction Via Resampling for Estimation Following Sequential Tests , 1997 .

[8]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[9]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[10]  Nigel Stallard,et al.  Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.

[11]  L Shen,et al.  An improved method of evaluating drug effect in a multiple dose clinical trial , 2001, Statistics in medicine.

[12]  Thomas Jaki,et al.  Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint , 2017, Statistics in medicine.

[13]  Mohammad F Huque,et al.  Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials , 2017, Statistics in medicine.

[14]  I. Lipkovich,et al.  Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials , 2017, Statistics in medicine.

[15]  Werner Brannath,et al.  Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.

[16]  Gerd K. Rosenkranz.  Bootstrap corrections of treatment effect estimates following selection , 2014, Comput. Stat. Data Anal..

[17]  Frank Bretz,et al.  TUTORIAL IN BIOSTATISTICS Adaptive designs for confirmatory clinical trials , 2022 .

[18]  Debashis Kushary,et al.  Bootstrap Methods and Their Application , 2000, Technometrics.

[19]  KyungMann Kim.  Group Sequential Methods with Applications to Clinical Trials , 2001 .

[20]  Harold B. Sackrowitz,et al.  Two stage conditionally unbiased estimators of the selected mean , 1989 .

[21]  Martin Posch,et al.  Adaptive designs for subpopulation analysis optimizing utility functions , 2014, Biometrical journal. Biometrische Zeitschrift.

[22]  Tim Friede,et al.  Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies , 2018, Statistical methods in medical research.

[23]  Martin Posch,et al.  Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials , 2016, PloS one.

[24]  Baldur P Magnusson,et al.  Group sequential enrichment design incorporating subgroup selection , 2013, Statistics in medicine.

[25]  M Kieser,et al.  Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.

[26]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[27]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[28]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[29]  T. Friede,et al.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.

[30]  Bart Spiessens,et al.  Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.

[31]  Sanjay Basu,et al.  Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment , 2017, Annals of Internal Medicine.

[32]  Nigel Stallard,et al.  Point estimates and confidence regions for sequential trials involving selection , 2005 .

[33]  Tim Friede,et al.  Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection , 2014, Journal of biopharmaceutical statistics.

[34]  J Zhang,et al.  What are minimal important changes for asthma measures in a clinical trial? , 1999, The European respiratory journal.

[35]  Jack Cuzick,et al.  Forest plots and the interpretation of subgroups , 2005, The Lancet.

[36]  Ravi Varadhan,et al.  A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. , 2013, Journal of clinical epidemiology.

[37]  W. Brannath,et al.  Selection and bias—Two hostile brothers , 2009, Statistics in medicine.

[38]  Isaac Dialsingh,et al.  Multiple testing problems in pharmaceutical statistics , 2011 .

[39]  George Y H Chi,et al.  A method for testing a prespecified subgroup in clinical trials , 2007, Statistics in medicine.

[40]  H Merabet,et al.  The design and analysis of sequential clinical trials , 2013 .

[41]  C. Mehta,et al.  Design and monitoring of multi‐arm multi‐stage clinical trials , 2017, Biometrics.

[42]  Oliver N Keene,et al.  Biomarkers for severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.

[43]  D Magirr,et al.  Simultaneous confidence intervals that are compatible with closed testing in adaptive designs , 2013, Biometrika.

[44]  C. Jennison,et al.  An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.

[45]  Nigel Stallard,et al.  A comparison of methods for constructing confidence intervals after phase II/III clinical trials , 2014, Biometrical journal. Biometrische Zeitschrift.

[46]  D Magirr,et al.  Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. , 2013, Statistics in medicine.